[{"id":"f5ce8c06-3250-40ff-b25a-dd3430d92b46","acronym":"","url":"https://clinicaltrials.gov/study/NCT07078604","created_at":"2025-07-26T13:31:46.938Z","updated_at":"2025-07-26T13:31:46.938Z","phase":"Phase 2","brief_title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT07078604","lead_sponsor":"University of Washington","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • daunorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • EP-101 STEMVAC • Leukine (sargramostim)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-07-22"},{"id":"33e40c58-3af8-42e4-bc3b-c3a150fef3e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05217147","created_at":"2022-02-05T18:28:09.104Z","updated_at":"2024-07-02T16:35:35.953Z","phase":"","brief_title":"An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma","source_id_and_acronym":"NCT05217147","lead_sponsor":"Hacettepe University","biomarkers":" ENG • IGFBP3","pipe":"","alterations":" ","tags":["ENG • IGFBP3"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 05/01/2018","start_date":" 05/01/2018","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 08/31/2021","study_completion_date":" 08/31/2021","last_update_posted":"2023-09-22"},{"id":"576ff15e-7a07-4123-9e2a-6f4a1fed07d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00813423","created_at":"2021-01-18T03:05:24.899Z","updated_at":"2024-07-02T16:35:41.219Z","phase":"Phase 1","brief_title":"Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy","source_id_and_acronym":"NCT00813423","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD31 • ENG • PECAM1 • BECN1","pipe":"","alterations":" ","tags":["CD31 • ENG • PECAM1 • BECN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 02/19/2010","start_date":" 02/19/2010","primary_txt":" Primary completion: 07/18/2023","primary_completion_date":" 07/18/2023","study_txt":" Completion: 07/18/2023","study_completion_date":" 07/18/2023","last_update_posted":"2023-08-02"},{"id":"536f855a-cf17-430d-ae0c-9454a6fe42ff","acronym":"THERRES","url":"https://clinicaltrials.gov/study/NCT05051423","created_at":"2021-09-21T11:53:36.284Z","updated_at":"2024-07-02T16:36:23.629Z","phase":"","brief_title":"\"Mechanisms and Biomarkers of Response and Resistance to Current Targeted Therapies in Gastric Cancer\" (THERRES)","source_id_and_acronym":"NCT05051423 - THERRES","lead_sponsor":"University of Medicine and Pharmacy Craiova","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2021-09-30"},{"id":"c9a4cec3-a91c-4bce-b61e-71cb0817eced","acronym":"","url":"https://clinicaltrials.gov/study/NCT01975519","created_at":"2021-01-18T08:59:39.076Z","updated_at":"2024-07-02T16:36:44.893Z","phase":"Phase 2a","brief_title":"A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT01975519","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 12/10/2013","start_date":" 12/10/2013","primary_txt":" Primary completion: 03/11/2019","primary_completion_date":" 03/11/2019","study_txt":" Completion: 03/11/2019","study_completion_date":" 03/11/2019","last_update_posted":"2020-05-20"},{"id":"48716b21-6535-4713-9a0f-a09659ac678b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01306058","created_at":"2021-01-18T05:18:51.239Z","updated_at":"2024-07-02T16:37:03.540Z","phase":"Phase 1/2","brief_title":"Sorafenib and TRC105 in Hepatocellular Cancer","source_id_and_acronym":"NCT01306058","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 02/11/2011","start_date":" 02/11/2011","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/09/2017","study_completion_date":" 06/09/2017","last_update_posted":"2019-01-23"},{"id":"8dd3f5a7-732d-4bef-9b49-824b3d62fff8","acronym":"EPHOS-B","url":"https://clinicaltrials.gov/study/NCT01104571","created_at":"2021-01-18T04:22:18.912Z","updated_at":"2025-02-25T15:51:00.378Z","phase":"Phase 3","brief_title":"Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer","source_id_and_acronym":"NCT01104571 - EPHOS-B","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" EGFR • HER-2 • ER • MYC • ERBB3 • FLT1 • CASP3 • CD31 • ENG • PECAM1","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 amplification • HER-2 expression • ER negative","tags":["EGFR • HER-2 • ER • MYC • ERBB3 • FLT1 • CASP3 • CD31 • ENG • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 amplification • HER-2 expression • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 257","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 08/30/2017","primary_completion_date":" 08/30/2017","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2018-09-17"},{"id":"9e38132f-f6aa-4337-816d-1a1db58ab598","acronym":"","url":"https://clinicaltrials.gov/study/NCT00835978","created_at":"2021-01-18T03:10:54.824Z","updated_at":"2024-07-02T16:37:21.625Z","phase":"Phase 2","brief_title":"Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer","source_id_and_acronym":"NCT00835978","lead_sponsor":"Pfizer","biomarkers":" FLT4 • MCAM • CD31 • ENG • PECAM1","pipe":"","alterations":" ","tags":["FLT4 • MCAM • CD31 • ENG • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Completed","enrollment":" Enrollment 213","initiation":"Initiation: 08/01/2009","start_date":" 08/01/2009","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2017-05-30"}]